Reach Us +447482876457
Human Umbilical Cord Blood Mesenchymal Stem Cell Promotes Neurogenesis In An Animal Model Of Alzheimer?s Disease | 5363
ISSN: 2157-7552

Journal of Tissue Science & Engineering
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Human umbilical cord blood mesenchymal stem cell promotes neurogenesis in an animal model of Alzheimer?s disease

International Conference on Tissue Science & Engineering

Jong Wook Chang

ScientificTracks Abstracts: J Tissue Sci Eng

DOI: 10.4172/2157-7552-S1.002

H uman umbilical cord blood-derived msenchymal stem cell (hUCB-MSC) has been regarded as a fascinating candidate of stem cell therapy in alzheimer?s disease (AD). Recently, we reported that transplantation of hUCB-MSC reduced amyloid plaques via release of soluble intercellular adhesion molecule-1 in vitro and in vivo. In addition, we observed that a certain secreted proteins of hUCB-MSC stimulate neurogenesis in a transgenic mice model of AD. These data suggested that secreted proteins of hUCB-MSC act simultaneously in microenvironment of AD. Based on these findings, we already finished Phase I clinical trial in Korea. In this presentation, I will briefly introduce our efforts to develop hUCB-MSC therapeutics for AD from the bench to clinical trial.
Chang has completed his Ph.D in 2005 from Gwangju-Institute of Science & Technology (GIST) and postdoctoral studies from Korea-Institute of Science & Technology (KIST). Now, he is the director of research division II in R&D Center of MEDIPOST Co., Ltd which is a leading biopharmaceutical company of cord blood MSC therapeutics in South Korea. He also has been worked as a project manager for phase I clinical trial for AD using hUCB- MSC. He has published more than 13 papers after 2008 in reputed journals regarding stem cells and serving as an editorial board member of World Journal of Stem Cells.
Leave Your Message 24x7